Nitin Naik, Frost & Sullivan

Nitin Naik Nitin has close to 20 years of healthcare industry knowledge, including 10 plus years of consulting expertise focusing on the pharmaceutical and biotechnology sector. His industry expertise covers key healthcare sectors from pharmaceuticals and biotechnology to clinical diagnostics and clinical research. Expertise in Translational R&D (Biologics & Small molecules), Oncology (Brain Tumors; Breast & Prostate Cancer), Antimicrobials (Nanopolymers, Peptides and Quorum Sensing compounds), In-vitro Toxicology. Nitin has detailed industry and therapeutic area expertise, including knowledge of key emerging and established markets from a market, regulatory and reimbursement point of view.  He has an in-depth understanding of healthcare markets across the world from government healthcare structures and policy to end user and market evaluations. Prior to his current position, Nitin spent 5-10 years each with GE Healthcare (national distributor), Frost & Sullivan Asia & A*STAR Singapore in various roles from strategy, marketing to in-licensing, portfolio management and market planning.  He has facilitated several regional and global strategic alliances.  At Frost & Sullivan Asia, he established a responsive, multi-million-dollar consulting business unit and he tripled revenues for Japan business in 2 years. At A*STAR, he championed business transformation initiatives to strengthen Singapore’s position # 1: Pharma Drug Development (D3) # 2: Diagnostics (DxD) Hub # 3: A*START Central #4: Biopharma Manufacturing Hub.  Received Excellence Award from Taiwan’s National Biotech agency to design the 5-year blue print for the local industry. Education: Advanced Management Program (Corporate Strategy & Finance) from Stanford-NUS, MBA (International Business-SPJIMR) and a Bachelor’s degree in Biomedical Engineering (Gold Medalist) from Bombay University.


2:25 PM - 2:45 PM

The Future of Clinical Trials Using AI

As cost pressures continue to escalate, AI/ML are becoming valuable tools to help sponsors more accurately predict the feasibility of trials in the design phase to mitigate the risk of delays and failure. Using AI in study design, and more effective study protocols, has the potential to reduce cycle time and cut costs to produce relatively faster ROI results. This session will cover how to integrate AI/ML into clinical trial design effectively including how using AI to analyze diverse and extensive data sets has the potential to shape insights from real-world data (RWD) into protocol designs.
  • Nitin Naik

    Nitin Naik Vice President-Global Life Sciences, Transformational Health Frost & Sullivan

Download Latest Agenda